Mereo BioPharma Group plc financial data

Symbol
MREO on Nasdaq
Location
London
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 732% % 23%
Debt-to-equity 18% % -72%
Return On Equity -75% % 59%
Return On Assets -64% % -8%
Operating Margin -3922% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 795,658,504 shares 2.6%
Common Stock, Value, Issued $3,134,000 USD 2.7%
Weighted Average Number of Shares Outstanding, Basic 799,947,013 shares 3.9%
Weighted Average Number of Shares Outstanding, Diluted 799,947,013 shares 3.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $0 USD
Research and Development Expense $22,393,000 USD 32%
General and Administrative Expense $25,268,000 USD 7.2%
Operating Income (Loss) $46,993,000 USD -20%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $41,573,000 USD 9.3%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $41,573,000 USD 8.3%
Earnings Per Share, Basic 0 USD/shares 0%
Earnings Per Share, Diluted 0 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $48,698,000 USD -40%
Assets, Current $52,407,000 USD -40%
Property, Plant and Equipment, Net $174,000 USD -45%
Operating Lease, Right-of-Use Asset $378,000 USD -58%
Assets $53,602,000 USD -40%
Accounts Payable, Current $879,000 USD -50%
Accrued Liabilities, Current $4,118,000 USD 17%
Liabilities, Current $6,016,000 USD -58%
Operating Lease, Liability, Noncurrent $0 USD -100%
Other Liabilities, Noncurrent $652,000 USD 15%
Liabilities $7,004,000 USD -57%
Accumulated Other Comprehensive Income (Loss), Net of Tax $10,910,000 USD 1.7%
Retained Earnings (Accumulated Deficit) $493,667,000 USD -8.3%
Stockholders' Equity Attributable to Parent $46,598,000 USD
Liabilities and Equity $53,602,000 USD -40%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $8,329,000 USD -4.2%
Net Cash Provided by (Used in) Financing Activities $422,000 USD
Net Cash Provided by (Used in) Investing Activities $320,000 USD 54%
Common Stock, Shares, Issued 795,484,404 shares 2.8%
Common Stock, Par or Stated Value Per Share 0 GBP/shares 0%
Interest Paid, Excluding Capitalized Interest, Operating Activities $7,000 USD 75%
Deferred Tax Assets, Valuation Allowance $215,021,000 USD 4.2%
Deferred Tax Assets, Gross $215,021,000 USD 4.2%
Operating Lease, Liability $397,000 USD -65%
Depreciation $140,000 USD -18%
Payments to Acquire Property, Plant, and Equipment $20,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $41,379,000 USD -19%
Lessee, Operating Lease, Liability, to be Paid $410,000 USD -67%
Property, Plant and Equipment, Gross $1,221,000 USD -4.5%
Operating Lease, Liability, Current $397,000 USD -46%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards $117,604,000 USD 6.3%
Operating Lease, Payments $800,000 USD -0.87%
Additional Paid in Capital $548,041,000 USD 2.2%
Amortization of Intangible Assets $106,000 USD -1.9%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Interest Expense $608,000 USD -55%